Acutaas Chemicals

ACUTAAS is trading at ₹3,770.80 as of November 5, 2026, maintaining a bullish technical structure across daily, weekly, and monthly timeframes. The stock sits near the upper end of its 252-day range (+88.9%), with price action consistently above key moving averages (SMA 20/50/200) and the Supertrend indicator on all observed horizons. Trend strength is established on the daily chart (ADX 25.53) and strong on weekly (ADX 52.12) and monthly (ADX 95.86) bases, supported by rising slopes in short-term moving averages.

Participation remains elevated following extreme volume anomalies in late October, including a +13.3% daily move with a volume ratio of 12.17 on October 27. However, recent price action shows signs of consolidation or minor reversal pressure, marked by a Doji on November 3 and a Bearish Engulfing pattern on November 2, suggesting a pause after significant gains. The stock is currently -5.8% from its available high, indicating some pullback from recent peaks.

Immediate resistance lies at the pivot level of ₹3,830.07 (1.57% above), while support is anchored at ₹3,706.23 (1.71% below). With annualized volatility at +43.7% and an ATR of 4.69%, the stock exhibits high sensitivity to intraday shifts. The current setup favors bulls as long as price holds above the immediate support zone; a break below ₹3,706.23 would test the next support at ₹3,635.17.

Acutaas Chemicals Limited (NSE: ACUTAAS) reported significant management restructuring and financial results during the seven-day window ending November 6, 2026. On November 2, the company appointed Dr. Ashish Kumar Pandey as Assistant Vice President—Operations (Cluster Head—Unit 2 & 3), designating him as Senior Management Personnel. Concurrently, Anurag Shukla and Uday Desai ceased being designated Senior Management Personnel due to a new reporting structure but remain employed as Heads of Unit 2 and Unit 3, respectively, reporting to Dr. Pandey. This internal reorganization was disclosed via NSE filings on November 2.

Additionally, the Board of Directors approved Standalone and Consolidated Unaudited Financial Results for the quarter ended September 30, 2026, on October 27, 2026. These results were published in the Financial Express on October 28, 2026, and accompanied by an earnings call transcript uploaded to the company website on November 2. Market data as of November 5, 2026, shows the stock trading at ₹3,770.80 with a market capitalization of approximately ₹30,925 crore. The stock has gained +115.4% year-to-date and +105.6% over the past year, though it is currently experiencing a -5.8% drawdown from recent highs.

Acutaas Chemicals Limited reported strong financial performance for Q2 and H1 FY27, with the Board approving results on October 27, 2026. Consolidated Q2 revenue rose 42.7% year-on-year to ₹4,369 million, driven by operational expansion including the inauguration of its South Korea semiconductor materials plant ahead of schedule. Consequently, management revised full-year FY27 guidance upward: revenue growth is now targeted at around 30% (previously 25%), and EBITDA margin guidance was raised to 38–40%. Statutory auditors issued unmodified limited review reports. In a separate governance update effective November 2, 2026, Dr. Ashish Kumar Pandey was appointed Assistant Vice President—Operations as Senior Management Personnel, while two existing senior managers transitioned to unit-head roles reporting to him under a new structure.

Acutaas Chemicals demonstrates a robust operational expansion in Q2 FY2026-27, with revenue from operations rising 32% sequentially to ₹437 crore and net profit jumping 64% to ₹123 crore. This follows strong year-on-year growth trends, including a 45% TTM sales increase and 96% TTM profit growth. Earnings quality remains high, evidenced by Cash from Operating Activity of ₹292 crore for the full year ended Mar 2026, significantly exceeding the prior year’s ₹118 crore.

The balance sheet reflects aggressive capacity building, with Fixed Assets growing to ₹1,115 crore (Mar 2026) and Property, Plant & Equipment reaching ₹1,005 crore as of Sep 2026. Despite this capital intensity, financial health is solid: borrowings decreased sharply to ₹15 crore in Sep 2026 from ₹36 crore in Mar 2026, while equity expanded to ₹1,920 crore. Return on Capital Employed (ROCE) improved markedly to 32% in Mar 2026, up from 20% the previous year. However, investors should monitor the Cash Conversion Cycle, which widened to 149 days in Mar 2026, driven primarily by an increase in Inventory Days to 149 days, suggesting potential working capital pressure amid rapid scaling.

Acutaas Chemicals exhibits strong multi-timeframe technical momentum, providing a constructive backdrop for the stock despite recent short-term volatility. As of November 5, 2026, the share price closed at ₹3,770.80, with the Supertrend indicator signaling a bullish trend across daily, weekly, and monthly charts. This alignment suggests underlying buying pressure persists even as the stock consolidates near its highs. The stock has delivered substantial long-term gains, rising +105.6% over the past year and +115.4% year-to-date, reflecting significant investor confidence. While the daily ADX of 25.53 indicates moderate trend strength, the monthly ADX is notably high at 95.86, underscoring the robustness of the longer-term uptrend. Key resistance levels sit at ₹3,830.07 (pivot) and ₹3,901.13 (high), while immediate support is found at ₹3,706.23. Investors should monitor whether the price can sustainably hold above the ₹3,706 level to maintain the bullish structure.

Acutaas Chemicals faces elevated volatility and near-term price resistance that warrant caution despite its strong long-term performance. The stock is currently trading at ₹3,770.80, down 0.2% on the day, with a market cap of approximately ₹309.25 billion. While the monthly trend remains bullish, the daily technical setup shows signs of consolidation; the Average Directional Index (ADX) for the daily timeframe is 25.53, indicating moderate trend strength, while the Supertrend direction is still bullish but under pressure from recent selling. The stock has pulled back 5.8% from its recent highs, contributing to a maximum drawdown of -17.5% over the observed period. This volatility is reflected in an annualized volatility of +43.7% and an ATR percentage of 4.69%, suggesting significant price swings. Immediate resistance sits at ₹3,830.07 (1.57% above current price), a pivot level that the stock failed to hold today after opening higher at ₹3,840.00. Investors should monitor whether the price can sustainably break above this pivot or if the current drawdown widens toward the next support level at ₹3,706.23.